Leptomeningeal Neoplasm clinical trials at University of California Health
1 research study open to eligible people
open to eligible people ages 18 years and up
This phase I/Ib trial studies the side effects and best dose of CB-839 HCl when given together with sapanisertib in treating patients with non-small cell lung cancer that has spread to other places in the body (advanced). CB-839 HCl and sapanisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
at UC Davis
Our lead scientists for Leptomeningeal Neoplasm research studies include Jonathan W. Riess.